Institute for Cancer Research
Institute for Cancer Research has since its foundation in 1954 played a central role within the field of cancer research both in Norway and internationally. The Institute has seven research departments and more than 320 employees, master students included. About 70% of the employees and projects are externally funded.
The Institute has internationally strong research groups within biochemistry, cell and tumor biology, genetics, radiation biology, immunology and cancer prevention. For more than 30 years there has been a close interaction between researchers at the Institute and cancer surgeons, oncologists and pathologists. This emphasis on translational science has resulted in numerous clinical protocols based on in-house research, and the Institute is a key partner in the Comprehensive Cancer Center, organizationally under the Division of Surgery and Cancer Treatment at Oslo University Hospital.
Scientific director
Scientific production - Institute for Cancer Research
| PubMed articles | Doctoral theses | |
| 2010 | so far | so far |
| 2009 | 164 | 22 |
| 2008 | 140 | 11 |
| 2007 | 153 | 16 |
| 2006 | 171 | 12 |
| 2005 | 158 | 12 |
Print this page [54580 visits]Latest news
University of Oslo's Research Prize to Johan Moan
This year's research prize from the University of Oslo goes to professor Johan Moan from the Department of Radiation Biology at the Institute for Cancer Research.
The prize amounts to NOK 250.000, and will be awarded during UiO's annual banquet on September 2nd.
JAMA article first-authored by Philip Wilkens
A study performed by research fellow and chiropractor Philip Wilkens from the orthopaedic centre at the Division of Surgery and Clinical Neuroscience confirms that glucosamine has no relieving effect on backache. The findings attract international attention, and are published in the prestigious journal "Journal of American Medical Association" (JAMA) (journal impact factor 31,7). The article - entitled "Effect of Glucosamine on Pain-related Disability in Patients with Chronic Low Back Pain and Degenerative Lumbar Osteoarthritis: A Randomized Controlled Trial" - is published in the July 7th issue of JAMA.
Sir Hans Krebs Medal to Harald Stenmark
At the 2010 FEBS Congress in Gothenburg, Harald Stenmark from the Centre for Cancer Biomedicine and the Institute for Cancer Research was awarded the Sir Hans Krebs Medal. This medal is awarded annually by the Federation of European Biochemical Societies for "outstanding achievements in Biochemistry and Molecular Biology or related sciences". Recent awardees include Nobel laureates Aaron Ciechanover (2006) and Tim Hunt (2008). After receiving the medal, Stenmark presented a plenary lecture entitled "How a lipid mediates tumour suppression".
Jun 30, 2010
Latest publications
Inst. for Cancer Research
Shiga Toxin Increases Formation of Clathrin-Coated Pits through Syk Kinase
PLoS One, 5 (7), e10944
PubMed 20668539
Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations
Eur J Clin Pharmacol (in press)
PubMed 20665013
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer
Mol Oncol (in press)
PubMed 20663721
Selected publications
Journal Impact Factor > 5, first or last author from the Institute for Cancer Research
Ubiquitination of alpha 5 beta 1 integrin controls fibroblast migration through lysosomal degradation of fibronectin-integrin complexes
Dev Cell, 19 (1), 148-59
PubMed 20643357
(Impact 12.9)
Photochemical internalization provides time- and space-controlled endolysosomal escape of therapeutic molecules
J Control Release (in press)
PubMed 20600406
(Impact 5.7)
Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein
Blood (in press)
PubMed 20574048
(Impact 10.4)
